[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

CCCC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.97%

Insider Buying (Last 12 Months): $31,735.20

Insider Selling (Last 12 Months): $0.00

C4 Therapeutics Insider Trading History Chart

C4 Therapeutics Share Price & Price History

^$1.51

▼ -0.06 (-3.82%)

As of 11/29/2023 01:00 AM ET

Days: 30 | 90 | 365

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

C4 Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/8/2023	Utpal Koppikar	Director	Buy	5,667	$5.60	$31,735.20	5,667
4/12/2022	Andrew Hirsch	CEO	Buy	10,000	$8.40	$84,000.00	10,000
12/17/2021	Malcolm Salter	Director	Sell	755	$30.25	$22,838.75
11/19/2021	Malcolm Salter	Director	Sell	755	$40.11	$30,283.05
10/15/2021	Malcolm Salter	Director	Sell	755	$44.94	$33,929.70
10/1/2021	Adam Crystal	Insider	Sell	15,000	$45.43	$681,450.00
9/27/2021	Elena Prokupets	Director	Sell	1,850	$50.04	$92,574.00
9/23/2021	Elena Prokupets	Director	Sell	19,180	$50.41	$966,863.80
9/21/2021	Elena Prokupets	Director	Sell	10,321	$50.14	$517,494.94
9/17/2021	Elena Prokupets	Director	Sell	10,840	$50.05	$542,542.00
9/15/2021	Elena Prokupets	Director	Sell	54,193	$48.82	$2,645,702.26
9/13/2021	Elena Prokupets	Director	Sell	6,660	$50.07	$333,466.20
9/10/2021	Elena Prokupets	Director	Sell	2,550	$50.00	$127,500.00
8/20/2021	Malcolm Salter	Director	Sell	755	$40.73	$30,751.15	13,672
8/2/2021	Elena Prokupets	Director	Sell	4,257	$45.01	$191,607.57
8/2/2021	Stewart L. Fisher	Insider	Sell	18,104	$45.00	$814,680.00
7/29/2021	Elena Prokupets	Director	Sell	11,336	$45.00	$510,120.00
7/29/2021	Jolie Siegel	Insider	Sell	12,500	$45.00	$562,500.00
7/16/2021	Malcolm Salter	Director	Sell	755	$37.37	$28,214.35	14,427
7/1/2021	Adam Crystal	Insider	Sell	15,000	$37.98	$569,700.00	15,000
6/18/2021	Malcolm Salter	Director	Sell	755	$37.19	$28,078.45	14,843
5/21/2021	Malcolm Salter	Director	Sell	755	$37.12	$28,025.60	15,598
4/5/2021	Adam Crystal	Insider	Sell	15,000	$37.77	$566,550.00	15,000

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for C4 Therapeutics (NASDAQ:CCCC)

74.88% of C4 Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

C4 Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2023	Jacobs Levy Equity Management Inc.	864,481	$1.61M	0.0%	+18.6%	1.754%
11/16/2023	Tudor Investment Corp Et Al	15,223	$28K	0.0%	N/A	0.031%
11/16/2023	Public Employees Retirement System of Ohio	71,163	$0.13M	0.0%	-65.7%	0.144%
11/15/2023	AQR Capital Management LLC	1,093,099	$2.03M	0.0%	+98.0%	2.218%
11/14/2023	Lynx1 Capital Management LP	1,019,230	$1.90M	1.3%	N/A	2.068%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	164,722	$0.31M	0.0%	-5.5%	0.334%
11/13/2023	Algert Global LLC	51,760	$96K	0.0%	-12.4%	0.105%
11/13/2023	Mariner LLC	126,491	$0.24M	0.0%	-10.8%	0.257%
11/13/2023	Acadian Asset Management LLC	28,014	$51K	0.0%	-78.1%	0.057%
11/13/2023	FMR LLC	121,165	$0.23M	0.0%	+121.2%	0.246%
11/9/2023	Citigroup Inc.	57,894	$0.11M	0.0%	+214.6%	0.117%
11/9/2023	UBS Group AG	321,609	$0.60M	0.0%	+19.2%	0.653%
11/8/2023	Charles Schwab Investment Management Inc.	248,252	$0.46M	0.0%	+7.5%	0.504%
11/7/2023	Barclays PLC	43,614	$81K	0.0%	+30.7%	0.089%
11/2/2023	M&T Bank Corp	140,020	$0.26M	0.0%	N/A	0.285%
10/24/2023	Raymond James & Associates	91,380	$0.17M	0.0%	+8.5%	0.186%
10/20/2023	Harbor Capital Advisors Inc.	70,703	$0.13M	0.0%	+20.6%	0.144%
9/21/2023	Barclays PLC	33,368	$92K	0.0%	-29.5%	0.068%
8/15/2023	Public Employees Retirement System of Ohio	207,456	$0.57M	0.0%	+5.3%	0.422%
8/15/2023	XTX Topco Ltd	201,033	$0.55M	0.1%	+494.1%	0.409%
8/15/2023	Y Intercept Hong Kong Ltd	75,900	$0.21M	0.0%	+142.0%	0.154%
8/15/2023	Goldman Sachs Group Inc.	230,566	$0.63M	0.0%	-33.3%	0.469%
8/15/2023	DRW Securities LLC	21,100	$58K	0.0%	N/A	0.043%
8/15/2023	Caxton Associates LP	26,721	$73K	0.0%	-31.4%	0.054%
8/15/2023	Point72 Middle East FZE	38,607	$0.11M	0.0%	+297.9%	0.078%
8/14/2023	PDT Partners LLC	21,432	$59K	0.0%	-72.7%	0.044%
8/14/2023	State of Wyoming	34,494	$95K	0.0%	N/A	0.070%
8/14/2023	Tower Research Capital LLC TRC	9,382	$26K	0.0%	+144.6%	0.019%
8/14/2023	ArrowMark Colorado Holdings LLC	309,755	$0.85M	0.0%	-95.1%	0.630%
8/14/2023	State of Wisconsin Investment Board	171,600	$0.47M	0.0%	+22.2%	0.349%
8/14/2023	TCG Crossover Management LLC	1,276,574	$3.51M	0.6%	+2.1%	2.595%
8/14/2023	State Street Corp	155,373	$0.43M	0.0%	-79.9%	0.316%
8/14/2023	Prelude Capital Management LLC	34,000	$94K	0.0%	N/A	0.069%
8/14/2023	Graham Capital Management L.P.	32,974	$91K	0.0%	N/A	0.067%
8/11/2023	Renaissance Technologies LLC	516,898	$1.42M	0.0%	+58.5%	1.051%
8/11/2023	Pale Fire Capital SE	19,200	$53K	0.0%	N/A	0.039%
8/11/2023	BlackRock Inc.	2,086,563	$5.74M	0.0%	-43.6%	4.242%
8/11/2023	B. Metzler seel. Sohn & Co. AG	66,276	$0.18M	0.0%	+265.8%	0.135%
8/11/2023	The Manufacturers Life Insurance Company	65,195	$0.18M	0.0%	-20.3%	0.133%
8/11/2023	Hsbc Holdings PLC	32,653	$90K	0.0%	+74.1%	0.066%
8/11/2023	Geode Capital Management LLC	438,959	$1.21M	0.0%	-47.8%	0.892%
8/11/2023	Northern Trust Corp	91,158	$0.25M	0.0%	-76.3%	0.185%
8/10/2023	Russell Investments Group Ltd.	78,133	$0.22M	0.0%	+32.4%	0.159%
8/10/2023	Charles Schwab Investment Management Inc.	231,034	$0.64M	0.0%	-27.1%	0.471%
8/10/2023	Citigroup Inc.	18,402	$51K	0.0%	+1,196.8%	0.038%
8/9/2023	Dimensional Fund Advisors LP	263,384	$0.72M	0.0%	-31.1%	0.537%
8/8/2023	Wasatch Advisors LP	7,199,491	$19.80M	0.1%	+26.0%	14.675%
8/7/2023	Acadian Asset Management LLC	128,060	$0.35M	0.0%	N/A	0.261%
8/3/2023	Barclays PLC	33,368	$92K	0.0%	-29.5%	0.068%
8/3/2023	Bank of New York Mellon Corp	22,281	$61K	0.0%	-85.3%	0.045%
7/25/2023	Raymond James & Associates	84,234	$0.23M	0.0%	+33.5%	0.172%
7/11/2023	Harbor Capital Advisors Inc.	58,647	$0.16M	0.0%	+10.1%	0.120%
7/10/2023	SG Americas Securities LLC	12,810	$35K	0.0%	-54.3%	0.026%
5/22/2023	Ameriprise Financial Inc.	80,135	$0.25M	0.0%	+107.3%	0.163%
5/18/2023	JPMorgan Chase & Co.	33,863	$0.11M	0.0%	-66.3%	0.069%
5/18/2023	New York State Common Retirement Fund	7,864	$25K	0.0%	-72.5%	0.016%
5/16/2023	Susquehanna Fundamental Investments LLC	17,572	$55K	0.0%	-45.9%	0.036%
5/16/2023	Susquehanna International Group LLP	268,067	$0.84M	0.0%	+675.6%	0.546%
5/16/2023	Jane Street Group LLC	100,741	$0.32M	0.0%	N/A	0.205%
5/16/2023	State Street Corp	774,221	$2.43M	0.0%	-68.4%	1.578%
5/16/2023	Squarepoint Ops LLC	107,632	$0.34M	0.0%	+96.7%	0.219%
5/16/2023	Geode Capital Management LLC	840,778	$2.64M	0.0%	+5.5%	1.714%
5/16/2023	AQR Capital Management LLC	606,465	$1.90M	0.0%	+120.5%	1.236%
5/16/2023	ArrowMark Colorado Holdings LLC	6,380,880	$20.04M	0.2%	+10.0%	13.005%
5/15/2023	Cubist Systematic Strategies LLC	14,560	$46K	0.0%	-67.7%	0.030%
5/15/2023	Two Sigma Advisers LP	400,300	$1.26M	0.0%	+53.1%	0.816%
5/15/2023	Two Sigma Investments LP	263,264	$0.83M	0.0%	+122.6%	0.537%
5/15/2023	Deutsche Bank AG	25,932	$81K	0.0%	+45.9%	0.053%
5/15/2023	Price T Rowe Associates Inc. MD	2,875,374	$9.03M	0.0%	-1.7%	5.860%
5/15/2023	XTX Topco Ltd	33,839	$0.11M	0.0%	+139.1%	0.069%
5/12/2023	Renaissance Technologies LLC	326,080	$1.02M	0.0%	+903.3%	0.665%
5/12/2023	Cresset Asset Management LLC	11,281	$35K	0.0%	-75.4%	0.023%
5/12/2023	Wasatch Advisors LP	5,716,021	$17.95M	0.1%	-1.0%	11.650%
5/12/2023	BlackRock Inc.	3,696,742	$11.61M	0.0%	+2.1%	7.535%
5/12/2023	Bank of America Corp DE	51,488	$0.16M	0.0%	-73.6%	0.105%
5/12/2023	HRT Financial LP	119,612	$0.38M	0.0%	N/A	0.244%
5/12/2023	UBS Group AG	162,650	$0.51M	0.0%	-39.8%	0.332%
5/12/2023	Martingale Asset Management L P	39,420	$0.12M	0.0%	+20.6%	0.080%
5/12/2023	Wellington Management Group LLP	124,810	$0.39M	0.0%	-7.4%	0.254%
5/12/2023	Panagora Asset Management Inc.	107,891	$0.34M	0.0%	N/A	0.220%
5/12/2023	Charles Schwab Investment Management Inc.	317,009	$1M	0.0%	-11.1%	0.646%
5/11/2023	M&T Bank Corp	72,000	$0.23M	0.0%	+17.5%	0.147%
5/11/2023	Cornercap Investment Counsel Inc.	48,047	$0.15M	0.0%	+82.8%	0.098%
5/11/2023	ExodusPoint Capital Management LP	10,551	$33K	0.0%	N/A	0.022%
5/10/2023	B. Metzler seel. Sohn & Co. AG	18,120	$57K	0.0%	N/A	0.037%
5/10/2023	Swiss National Bank	73,900	$0.23M	0.0%	-10.5%	0.151%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	113,893	$0.36M	0.0%	+687.8%	0.232%
5/9/2023	Y Intercept Hong Kong Ltd	31,362	$98K	0.0%	N/A	0.064%
5/9/2023	Russell Investments Group Ltd.	59,034	$0.19M	0.0%	+30.5%	0.120%
5/4/2023	Barclays PLC	47,363	$0.15M	0.0%	-54.3%	0.097%
4/28/2023	SG Americas Securities LLC	28,013	$88K	0.0%	-32.6%	0.057%
4/26/2023	Harbor Capital Advisors Inc.	53,278	$0.17M	0.0%	+113.7%	0.109%
2/16/2023	Alliancebernstein L.P.	52,000	$0.31M	0.0%	+9.0%	0.106%
2/15/2023	Public Employees Retirement System of Ohio	197,045	$1.16M	0.0%	-15.1%	0.402%
2/15/2023	CI Private Wealth LLC	11,380	$67K	0.0%	N/A	0.023%
2/15/2023	State of Wisconsin Investment Board	134,674	$0.80M	0.0%	+20.7%	0.275%
2/15/2023	Susquehanna Fundamental Investments LLC	32,496	$0.19M	0.0%	N/A	0.066%
2/15/2023	Soleus Capital Management L.P.	2,440,843	$14.40M	2.1%	+69.3%	4.985%
2/15/2023	Squarepoint Ops LLC	54,721	$0.32M	0.0%	+157.5%	0.112%
2/15/2023	Morgan Stanley	379,199	$2.24M	0.0%	+10.1%	0.775%

Data available starting January 2016

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $1.51

$1.51

$1.69

50 Day Range

MA: $1.70

$1.32

$2.19

52 Week Range

Now: $1.51

$1.23

$9.41

Volume

181,905 shs

Average Volume

701,620 shs

Market Capitalization

$74.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Who are the company insiders with the largest holdings of C4 Therapeutics?: C4 Therapeutics' top insider shareholders include:
Andrew Hirsch (CEO)
Utpal Koppikar (Director)
Malcolm Salter (Director)
Learn More about top insider investors at C4 Therapeutics.
Who are the major institutional investors of C4 Therapeutics?: C4 Therapeutics' top institutional investors include:
AQR Capital Management LLC — 2.22%
Lynx1 Capital Management LP — 2.07%
Jacobs Levy Equity Management Inc. — 1.75%
UBS Group AG — 0.65%
Charles Schwab Investment Management Inc. — 0.50%
Connor Clark & Lunn Investment Management Ltd. — 0.33%
Learn More about top institutional investors of C4 Therapeutics stock.
Which major investors are selling C4 Therapeutics stock?: In the last quarter, CCCC stock was sold by these institutional investors:
Public Employees Retirement System of Ohio
Acadian Asset Management LLC
Mariner LLC
Connor Clark & Lunn Investment Management Ltd.
Algert Global LLC
Which major investors are buying C4 Therapeutics stock?: In the previous quarter, CCCC stock was bought by institutional investors including:
Lynx1 Capital Management LP
AQR Capital Management LLC
M&T Bank Corp
Jacobs Levy Equity Management Inc.
FMR LLC
UBS Group AG
Citigroup Inc.
Charles Schwab Investment Management Inc.
During the last year, these company insiders have bought C4 Therapeutics stock:
Andrew Hirsch (CEO)
Utpal Koppikar (Director)
Learn More investors buying C4 Therapeutics stock.

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

CCCC Insider Trading

C4 Therapeutics Insider Trading History Chart

C4 Therapeutics Share Price & Price History

C4 Therapeutics Insider Trading History

SEC Filings (Institutional Ownership Changes) for C4 Therapeutics (NASDAQ:CCCC)

Institutional Buying and Selling by Quarter

C4 Therapeutics Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of C4 Therapeutics?

Who are the major institutional investors of C4 Therapeutics?

Which major investors are selling C4 Therapeutics stock?

Which major investors are buying C4 Therapeutics stock?